Core Viewpoint - The announcement highlights the approval of the clinical trial registration application (IND) for the innovative drug TUL108 by the FDA, marking a significant milestone for the company in the field of anti-infection treatments [1] Group 1: Drug Development - The clinical trial registration application for TUL108, a novel broad-spectrum β-lactamase inhibitor, was approved by the FDA, with IND number 178724 [1] - TUL108 is designed to treat infections caused by both Gram-negative and Gram-positive bacteria, including complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), lung infections, and bloodstream infections [1] - The drug shows high sensitivity against carbapenem-resistant Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, providing comprehensive coverage for clinically urgent carbapenem-resistant Gram-negative bacteria [1] Group 2: Strategic Positioning - The development of TUL108 is expected to strengthen the company's competitive position in the anti-infection sector [1] - The company aims to continue its commitment to new product development, enhancing its competitiveness and creativity within the pharmaceutical industry [1] - The anticipated success of TUL108 is projected to generate greater returns for the company and its shareholders [1]

Core Viewpoint - The approval of the IND for TUL108 by the FDA marks a significant milestone for the company, enhancing its position in the anti-infection sector and promising potential returns for shareholders [1] Group 1: Product Development - The company announced that its wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., received FDA approval for the clinical trial registration application of TUL108, a novel broad-spectrum β-lactamase inhibitor [1] - TUL108 is designed to treat infections caused by both Gram-negative and Gram-positive bacteria, including complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), lung infections, and bloodstream infections [1] - The drug shows high sensitivity against carbapenem-resistant Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, addressing critical clinical needs for coverage against carbapenem-resistant Gram-negative bacteria [1] Group 2: Strategic Positioning - The development of TUL108 is expected to strengthen the company's competitive advantage in the anti-infection field [1] - The company plans to continue its commitment to new product development, aiming to enhance its competitiveness and creativity within the pharmaceutical industry [1] - The anticipated success of TUL108 is projected to generate greater returns for the company and its shareholders [1]

Core Viewpoint - The announcement highlights the FDA approval of the clinical trial registration application for TUL108, a novel broad-spectrum β-lactamase inhibitor developed by the company, which is expected to enhance its competitive position in the anti-infection field [1] Group 1: Product Development - The clinical trial registration application (IND) for TUL108 was approved by the FDA, with IND number 178724, set to commence on January 28, 2026 [1] - TUL108 is designed to treat infections caused by both Gram-negative and Gram-positive bacteria, including complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), lung infections, and bloodstream infections [1] - The drug shows high sensitivity against carbapenem-resistant Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, providing comprehensive coverage for clinically urgent Gram-negative bacteria resistant to carbapenems [1] Group 2: Strategic Implications - The development of TUL108 is expected to strengthen the company's position in the anti-infection sector [1] - The company aims to continue its commitment to new product development, enhancing its competitiveness and creativity within the pharmaceutical industry [1] - The anticipated success of TUL108 is projected to generate greater returns for the company and its shareholders [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 注射用 TUL108 是由本公司自主設計並研發的一種新型超廣譜 β-內醯胺酶抑制劑，擬 用於治療由革蘭氏陰性菌或革蘭氏陽性菌所引起的感染，包括複雜性尿路感染（cUTI）、 複雜性腹腔感染（cIAI）及肺部感染和血流感染。TUL108 聯合美羅培南對碳青霉烯 類耐藥大腸埃希菌、肺炎克雷伯菌、銅綠假單胞菌及鮑曼不動桿菌等均具有高度敏感 性，針對臨床極待解决的對碳青霉烯耐藥的革蘭陰性菌可實現全覆蓋。 注射用 TUL108 的研發將強化本公司於抗感染領域的優勢地位。未來，本公司將繼續 致力於新產品研發，持續提升於醫藥行業的競爭力及創造力，預期將為本公司及其股 東創造更大收益。 承董事會命 聯邦制藥國際控股有限公司 主席 蔡海山 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 ( 於開曼群島成立之有限公司 ) (股份代號: 3 ...

Investment Rating - The report indicates a "Buy" rating for several companies within the pharmaceutical sector, including 恒瑞医药 (Hengrui Medicine), 百济神州-U (BeiGene), and others [22]. Core Insights - The pharmaceutical industry has seen a significant increase in BD (business development) activities, with Chinese pharmaceutical companies securing upfront payments exceeding $7.03 billion in 2025, marking a year-on-year growth of over 226.8% [15][20]. - The industry has a total market capitalization of approximately 544.85 billion yuan, with a TTM (trailing twelve months) P/E ratio of 38.5, significantly higher than the 14.1 P/E ratio of the CSI 300 index [3][6]. - The best-performing sub-sectors this week include offline pharmacies, hospitals, and medical R&D outsourcing, with year-to-date increases of 17.2%, 14.8%, and 10.7%, respectively [6][31]. Summary by Sections Industry Performance - The pharmaceutical index decreased by 0.39% this week, outperforming the CSI 300 index by 0.23 percentage points. Year-to-date, the pharmaceutical sector has risen by 6.66%, surpassing the CSI 300 index by 5.10 percentage points [6][24]. - The current valuation level (P/E-TTM) for the pharmaceutical industry stands at 30.31 times, with a premium of 65.36% over the entire A-share market [6][26]. Business Development Trends - In 2025, the domestic dual-antibody BD projects achieved upfront payments of $3.5 billion, a staggering increase of 414.7%, accounting for 49.8% of all BD upfront payments for the year [16]. - The ADC (Antibody-Drug Conjugates) sector has also seen substantial growth, with upfront payments reaching $1.63 billion, a 676.2% increase year-on-year [17]. - The GLP-1RA (Glucagon-Like Peptide-1 Receptor Agonists) segment reported upfront payments of $470 million, reflecting a 109.8% increase compared to 2024 [18]. Notable Collaborations - The report highlights significant collaborations, such as 舶望制药 (Bohua Pharmaceutical) partnering with Novartis to explore the potential of siRNA in hypertension treatment, securing an upfront payment of $160 million [19]. - The MNC (Multinational Corporation) procurement model remains dominant, with local companies securing $4.71 billion in upfront payments from MNCs, representing 67.0% of total BD upfront payments [20]. Recommended Companies - The report suggests a robust investment strategy focusing on companies like 恒瑞医药 (Hengrui Medicine), 百济神州-U (BeiGene), and others, which are expected to benefit from innovation and international expansion [20][21].

Core Viewpoint - The global GLP-1 market is shifting, with multinational pharmaceutical companies increasingly focusing on Chinese biopharmaceutical assets, a trend expected to peak in 2025 and be confirmed in early 2026 [5] Group 1: Market Dynamics - The competition in the weight loss and metabolic disease market is evolving from single product competition to a comprehensive contest involving multiple mechanisms, indications, and long-term medication [5] - Multinational pharmaceutical companies are experiencing anxiety regarding pipeline breadth and technological reserves, with China emerging as a key source for supplementing GLP-1 pipelines [5] - Over the past decade, the role of Chinese innovative drug companies has shifted from introducing overseas technology to exporting self-developed assets [5] Group 2: Asset Development - Chinese companies have accumulated a number of candidates in the GLP-1 field, particularly in dual-target, triple-target, and oral formulations, with several in Phase II and III [5] - These assets are characterized by preliminary validation of scientific pathways and identifiable clinical risks, making them valuable for multinational companies to quickly fill their pipelines through licensing or acquisition [5] Group 3: Transaction Highlights - Novo Nordisk made a significant move by securing rights to a triple-target agonist, UBT251, with a payment structure of $200 million upfront and up to $1.8 billion in milestone payments, reflecting a strategic choice to rebuild its next-generation weight loss product lineup [7] - Regeneron entered a licensing agreement with Hansoh Pharma worth over $2 billion for a GLP-1/GIP dual-target agonist in Phase III, aiming to strengthen its position in the metabolic disease field [7] - Pfizer, after terminating two late-stage oral GLP-1 candidates due to safety issues, acquired Metsera for nearly $10 billion and entered a licensing agreement with YaoPharma for an early-stage oral GLP-1 candidate, demonstrating a cautious approach to re-entering the oral weight loss drug market [7] Group 4: Strategic Implications - These transactions signal that multinational pharmaceutical companies are preparing for the second phase of competition in the GLP-1 market, focusing on efficacy limits, medication convenience, long-term safety, and combination therapy potential [8] - The shift indicates a structural adjustment in the global pharmaceutical industry, with China transitioning from merely a clinical trial and production base to a significant technology supplier in key therapeutic areas [8]

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Insights - The report highlights that the pharmaceutical sector is showing resilience, with a focus on capturing opportunities from companies that can deliver on their growth potential. The report suggests that investors should continue to allocate to pharmaceutical bottom assets as fund holdings have returned to a low level [3][10] - The report indicates that the A-share funds' top ten holdings in the pharmaceutical sector account for 9.15%, a decrease of 1.93 percentage points from the previous period. Excluding pharmaceutical funds, the allocation drops to 3.43%, down 1.39 percentage points [3][10] - The report emphasizes the strong performance of certain pharmaceutical companies, particularly in innovative drugs and upstream life sciences, with notable profit growth forecasts for companies like Zhaoyan New Drug and Kangchen Pharmaceutical [3][10] Summary by Sections Market Dynamics - The pharmaceutical sector has outperformed the broader market, with a return of 6.66% compared to the CSI 300's 1.57% since the beginning of 2026, indicating a 5.10 percentage point advantage [14] - Recent performance shows a mixed trend, with pharmaceutical commercial, traditional Chinese medicine, and medical devices showing positive growth, while chemical pharmaceuticals and medical services have declined [10][14] Valuation Metrics - The current valuation of the pharmaceutical sector is at 23.3 times PE based on 2026 earnings forecasts, which is a premium of 11.3% compared to the overall A-share market (excluding financials) at approximately 21.0 times PE [17] - Using the TTM valuation method, the pharmaceutical sector is valued at 30.3 times PE, which is below its historical average of 34.9 times PE, indicating a relative premium of 11.2% over the broader market [17] Recommended Stocks - Key recommended stocks include WuXi Biologics, Sangfor Technologies, Tigermed, and others, with an average increase of 13.41% in January, outperforming the pharmaceutical sector by 6.74 percentage points [26][27] - The report notes that the top ten pharmaceutical stocks held by public funds include companies like Hengrui Medicine and WuXi AppTec, with a strong preference for innovative drugs and leading players in niche markets [3][10]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The pharmaceutical and biotechnology sector is expected to experience a cyclical recovery in raw material prices for animal health products in 2026, following a prolonged decline due to oversupply and weak downstream demand [5][49] - Heparin and iodine contrast agent raw materials are currently at the bottom of their price cycles, with heparin prices declining sharply in Q4 2023 due to market pressures, while iodine prices have seen a recent recovery driven by strong demand from other industries [6][51] Summary by Sections Industry Trends - The pharmaceutical and biotechnology sector saw a decline of 0.39% in the third week of January 2026, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th among 31 sub-industries [7][58] - The offline pharmacy segment experienced the highest increase, rising by 9.66%, while the medical research outsourcing segment faced the largest decline, dropping by 3.96% [7][61] Price Trends - The average price of florfenicol has decreased from the range of 400-700 RMB/kg to a recent range of 100-200 RMB/kg, indicating a significant drop to historical lows [5][47] - Heparin raw material prices have stabilized after a period of decline, while iodine raw material prices are expected to rise again in 2025 due to increased demand [51][55] Recommended Stocks - Monthly recommended stocks include WuXi AppTec, 3SBio, and CSPC Pharmaceutical Group, while weekly recommendations feature companies like Kanglong Chemical and Yao Ming He Lian [8]

Investment Rating - The report indicates a significant acceleration in BD (Business Development) overseas for Chinese innovative drugs, suggesting a positive investment outlook for the industry [3]. Core Insights - The number of BD projects, upfront payments, and total amounts for Chinese pharmaceutical companies significantly increased in 2025, with 165 projects, over $7.03 billion in upfront payments (up 226.8% year-on-year), and a total amount of $136.68 billion (up 192.2% year-on-year) [2][7]. - The report highlights a focus on dual antibodies (双抗), antibody-drug conjugates (ADC), GLP-1 receptor agonists (GLP1RA), and small nucleic acids as key areas for BD overseas [2][3]. Summary by Sections BD Project Growth - In 2025, the quarterly breakdown of BD projects shows 41, 43, 30, and 51 projects in Q1, Q2, Q3, and Q4 respectively, with significant year-on-year increases [2][7]. - Upfront payments for each quarter were $0.9 billion, $2.0 billion, $1.86 billion, and $2.27 billion, reflecting substantial growth rates [2][7]. Outbound BD Models - The predominant model for BD remains license in/out, while the NewCo/Co-CoJV model is gaining attention, with limited successful cases of independent commercialization [2][12][13]. - In 2025, MNCs (Multinational Corporations) accounted for $4.71 billion in upfront payments, representing 67% of total BD upfront payments [12]. Key Drug Categories - Dual antibodies saw a remarkable increase, with $3.5 billion in upfront payments (up 414.7%) and a total amount of $21.85 billion (up 361.5%) in 2025 [2][18]. - ADCs emerged as a significant focus, with $1.63 billion in upfront payments (up 676.2%) and a total amount of $21.13 billion (up 390.6%) [2][26]. - GLP-1RA projects achieved $470 million in upfront payments, marking a 109.8% increase, with a total amount of $9.6 billion [2]. NewCo Model - The NewCo model has facilitated overseas BD, with a total of $350 million in upfront payments and $13.74 billion in potential total amounts from 2023 to 2025 [17]. - In 2025, NewCo projects secured $110 million in upfront payments and $4.76 billion in potential total amounts [17]. Clinical Development Stages - Approximately 62% of molecules were in early clinical stages (pre-clinical to before Phase II) at the time of BD, indicating a trend towards early-stage licensing [8][9].

Core Viewpoint - The Chinese innovative drug business development (BD) for overseas licensing reached a record high of $135.655 billion in total transaction value for 2025, with a significant increase in upfront payments and transaction numbers compared to previous years [1][2]. Group 1: Market Performance - The China Securities Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index (930965) showed mixed performance among its constituent stocks, with Times Angel leading at a 4.83% increase [1]. - The Hong Kong pharmaceutical ETF (159718) was quoted at 0.96 yuan [1]. Group 2: Industry Developments - The innovative drug BD overseas licensing transactions in China for 2025 totaled $135.655 billion, with upfront payments of $7 billion and 157 transactions, all marking historical highs [2]. - Notable collaborations include Rongchang Biopharma's PD-1/VEGF dual antibody RC148 receiving a $650 million upfront payment from AbbVie, and Yilian Biopharma's partnership with Roche on B7H3-targeted ADC [2]. - GSK's Bepirovirsen for chronic hepatitis B showed positive results in Phase III trials, and Arrowhead announced advancements in RNAi therapies for weight loss, validating the clinical value of small nucleic acid drugs [2]. Group 3: Investment Outlook - The 44th Annual J.P. Morgan Healthcare Conference revealed positive updates from leading global pharmaceutical companies, with significant BD transactions and improved forecasts from CXO companies like WuXi AppTec [2]. - The global pharmaceutical industry remains robust, with innovation in drugs and medical devices continuing to be the main investment theme [2].